Why is the ResMed share price sliding on Wednesday?

ResMed shares are coming under selling pressure today.

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price is slipping on Wednesday.

Shares in the S&P/ASX 200 Index (ASX: XJO) healthcare stock closed yesterday trading for $23.76. In morning trade today, shares are swapping hands for $23.46 apiece, down 1.3%.

For some context, the ASX 200 is up 0.1% at this same time.

Here's what's happening.

Cropped shot of a young female scientist working on her computer in the laboratory.

Image source: Getty Images

Why is the ResMed share price slipping?

Much of this morning's sell-off in the ResMed share price has nothing to do with the company itself. Or with any fresh news relating to potentially competing global health advancements in sleep technology, for that matter.

Instead, investors are hitting the sell button because the ASX 200 healthcare stock is trading ex-dividend today.

That means investors buying shares today will no longer be eligible for ResMed's 4.8 US cents per share interim dividend. That income payout will instead go to shareholders who owned the stock at market close yesterday.

It's common for a company's shares to fall on the day they trade ex-dividend, as we see with the ResMed share price today. Similarly, you'll often see shares climb in the lead-up to their ex-dividend date, as income investors snap up shares to secure that payout.

Unlike most ASX 200 dividend shares, ResMed pays out quarterly dividends, generally unfranked.

At the current share price, ResMed trades on a trailing yield of 1.3%.

What's been happening with the ASX 200 healthcare stock?

Management declared the 4.8 US cent per share dividend when ResMed reported its quarterly results on 27 October.

Highlights included a 16% increase in revenue to US$1.1 billion and a 5% boost in income from operations.

Despite some strong metrics, the ResMed share price closed down 4% on the day the company reported.

Looking ahead, ResMed CEO Mick Farrell was optimistic about the company's growth prospects.

"Our ability to meet global demand with technologies … has positioned us well to continue growing across global markets, with particularly strong growth this quarter in Europe, Asia, and beyond," he said.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Five healthcare workers standing together and smiling.
Healthcare Shares

3 ASX 200 healthcare shares to buy amid sector rout

The experts are backing these stocks for price growth.

Read more »

Researchers and doctors with futuristic 3D hologram overlay for body anatomy or DNA in hospital clinic.
Healthcare Shares

Are investors taking a big gamble chasing 4DX shares higher and higher?

Investor interest in this ASX healthcare tech stock is booming.

Read more »

A group of people in a corporate setting do a collective high five.
Broker Notes

3 reasons to buy Ramsay Health Care shares today

A leading analyst expects Ramsay Health Care shares to keep outperforming in the months ahead.

Read more »

Half a man's face from the nose up peers over a table.
Healthcare Shares

If I could buy only 1 ASX 200 share right now, it would be…

This stock looks underpriced and oversold to me.

Read more »

woman testing substance in laboratory dish, csl share price
Healthcare Shares

CSL shares slide again in March — but is a comeback brewing?

Brokers remain upbeat and see upside up to 95% for the biotech stock.

Read more »

A female athlete in green spandex leaps from one cliff edge to another representing 3 ASX shares that are destined to rise and be great
Broker Notes

Up 57% since February, why Telix shares could keep leaping higher in 2026

A leading analyst believes investors are undervaluing Telix shares. But why?

Read more »

A woman has a thoughtful look on her face as she studies a fan of Australian 20 dollar bills she is holding on one hand while he rest her other hand on her chin in thought.
Healthcare Shares

Is it time to get greedy with CSL shares?

This ASX healthcare giant is out of favour, but that may be where opportunity starts.

Read more »

Stressed, unhappy, and tired scientist with a headache working on a computer in a lab.
Healthcare Shares

3 ASX 200 healthcare shares at multi-year lows

Does this present a buying opportunity?

Read more »